MaaT Pharma Announces the Availability of the 2021 Universal Registration Document
06 Juli 2022 - 6:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
microbiome-based ecosystem therapies dedicated to improving
survival outcomes for patients with cancer, today announced the
availability of its Universal Registration Document for the fiscal
year ending December 31, 2021, filed with the French Financial
Markets Authority (Autorité des Marchés Financiers) on July 5, 2022
under the visa number R.22-032.
The Universal Registration Document 2021 is available free of
charge to the public under the conditions provided for by the
regulations in place, and can be accessed on the MaaT Pharma's
website – Investors section – Regulated information
(www.maatpharma.com/) and on the AMF website
(www.amf-france.org).
Upcoming financial communication and investor conference
participation
- July 28, 2022 – Revenues and Cash Position Quarter 2*
- September 12-14, 2022 - H.C. Wainwright 24th Annual Global
Investment Conference
- September 15 - 16, 2022 – KBC Securities Life Sciences
Conference
- September 29, 2022 – Half-year Results 2022*
*Indicative calendar that may be subject to change.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, a Phase 3 clinical trial for patients with acute GvHD,
following the achievement of its proof of concept in a Phase 2
trial. Its powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of its pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions.
The company’s Microbiome Ecosystem Therapies are produced
through a standardized cGMP manufacturing and quality control
process to safely deliver the full diversity of the microbiome, in
liquid and oral formulations. MaaT Pharma benefits from the
commitment of world-leading scientists and established
relationships with regulators to support the integration of the use
of microbiome therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220706005582/en/
MaaT Pharma – Investor relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com MaaT Pharma -media relations Pauline
RICHAUD Senior PR & Corporate Communications Manager +33 6 07
55 25 36 prichaud@maat-pharma.com Trophic Communications -
Corporate and medical Communications Jacob VERGHESE or
Gretchen SCHWEITZER +49 (0)89 2070 89831 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024